Pataday Once Daily Relief

(olopatadine)

ApprovedSmall molecule

Pataday Once Daily Relief is one of 35 small molecule programs targeting Allergic Conjunctivitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Allergic ConjunctivitisCompleted

AllergyActive, not recruiting

Allergic ConjunctivitisApproved

Completed

AllergyPreclinical

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Allergy

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

1 2

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

6 3

Claritin

PPerrigo Company

Approved

1 4

Nexium

DDexcel Pharma Technologies Ltd.

Approved

1 5

Flagyl

DDePuy Orthopaedics

Approved

1 6

Potassium Citrate

MMission Pharmacal

Approved

1 7

Levaquin

WWim Janssens

Approved

1 8

Achromycin V

WWyeth-Lederle Vaccines

Approved

1 9

Allegra

CChattem

Approved

1 10

Pataday Once Daily Relief

Novartis

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Conjunctivitis3 trials

A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

Terminated·MMati Therapeutics Inc.·Phase 2·NCT01287338·143 enrolled

AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02161146·240 enrolled

A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis

Completed·GGreiner, Jack V., OD DO PhD·Phase 4·NCT00655109·60 enrolled

Allergy2 trials

Olopatadine Eye Drops and Allergy Skin Testing

Completed·VVanderbilt University Medical Center·N/A·NCT00775658·24 enrolled

Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms

Completed·UUniversity of Chicago·Phase 4·NCT01007253·21 enrolled

MPA1 trial

An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo

Withdrawn·OORA, Inc.·Phase 4·NCT01076439

Acute Lymphoblastic Leukemia1 trial

Effect of Olopatadine on Allergic Tear Mediators

Completed·UUniversity of Wisconsin, Madison·N/A·NCT00609128·21 enrolled

Conjunctivitis1 trial

Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02478398·1,025 enrolled

1 more indication

Unspecified1 trial

Mast-Cell Stabilizing Effects of Olopatadine

Completed·AAlcon Research·Phase 4·NCT00389025·24 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 18, 1996

PATADAY TWICE DAILY RELIEF

NDA NDA020688

Dec 22, 2004

PATADAY ONCE DAILY RELIEF

NDA NDA021545

Apr 15, 2008

PATANASE

NDA NDA021861

Jan 30, 2015

PATADAY ONCE DAILY RELIEF

NDA NDA206276

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for olopatadine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — olopatadine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for olopatadine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA206276). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Pataday Once Daily Relief. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Patent Landscape[5]

Patent Cliff

May 19, 2032

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8791154May 19, 2032

9533053May 19, 2032

Pataday Once Daily Relief

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Conjunctivitis3 trials

Allergy2 trials

MPA1 trial

Acute Lymphoblastic Leukemia1 trial

Conjunctivitis1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News